Hikma Signs Licensing, Distribution, and Supply Agreement with Basilea Pharmaceutica International for Antibiotic Zevtera
Under the terms of the agreement, Hikma will have the exclusive rights to register, distribute and market Zevtera in the Middle East and North America.
Hikma Pharmaceuticals announced that it has entered into an exclusive licensing, supply, and distribution agreement with biopharmaceutical company Basilea Pharmaceutica International for its new generation cephalosporin Zevtera (ceftobiprole medocaril). Zevtera, a new intravenous antibiotic developed for the treatment of pneumonia, has received approvals in 13 European countries and Canada. The antibiotic has been launched in Germany, France, Italy, the United Kingdom.
Under the terms of the agreement, Hikma will have the exclusive rights to register, distribute and market Zevtera in the Middle East and North America.
Source: Hikma
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
